The drug, Kisunla, made by Eli Lilly, is the latest in a new class of treatments that could modestly slow cognitive decline in initial stages of the disease but also carry safety risks.
Bev Krol of Phoenix has been a participant in a trial for the drug donanemab for nearly three years. Her husband, Mark, said she began being forgetful about six years ago.
Login
